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MicroRNAs are key regulators of gene expression that control stem cell fate by post-
transcriptional down-regulation of hundreds of target genes via seed-pairing in their 
3’ untranslated region. In fact, miRNAs tightly regulate fundamental stem cell 
processes, like self-renewal, proliferation and differentiation; therefore, miRNA 
deregulation may contribute to the development of solid tumours and haematological 
malignancies.  
MiR-382-5p has been found to be upregulated in patients with myeloid neoplasms 
but its role in normal hematopoiesis is still unknown. Here we demonstrated that miR-
382-5p overexpression in CD34+ hematopoietic stem/progenitor cells leads to a 
significant decrease of megakaryocyte precursors coupled to increase of granulocyte 
ones. Furthermore, by means of a computational analysis using different prediction 
algorithms, we identified several putative mRNA targets of miR-382-5p that are 
downregulated upon miRNA overexpression (i.e. FLI1, GATA2, MAF, MXD1, RUNX1 
and SGK1). Among these, we validated MXD1 as real target of miR-382-5p by 
luciferase reporter assay. Finally, we showed that MXD1 knockdown mimics the 
effects of miR-382-5p overexpression on granulocyte and megakaryocyte 
differentiation of CD34+ cells. 
Overall, our results demonstrated that miR-382-5p expression favours the expansion 
of granulocyte lineage and impairs megakaryocyte commitment through MXD1 down-
regulation. Therefore, our data showed for the first time that the miR-382-5p/MXD1 
axis plays a critical role in myelopoiesis by affecting the lineage choice of CD34+ 
hematopoietic stem/progenitor cells.  
 
 















































































































































































































































































































































































MicroRNAs (miRNAs) are a large class of small noncoding RNAs that act as post-
transcriptional regulators of gene expression (1). miRNAs simultaneously modulate 
the expression of several targets by binding to the 3’-untraslated region (3’-UTR) of 
the mRNAs, resulting in mRNA destabilization and/or translational inhibition (2).  
In the last decade, growing evidence has unravelled the role of miRNAs as key 
regulators of stem cell fate by modulating essential processes like self-renewal, 
proliferation and differentiation. In particular, the combinatorial expression of miRNAs 
can precisely characterize specific cell types and regulate different phases of 
differentiation (3, 4). Moreover, recent advancements in computational and molecular 
biology have highlighted the existence of regulatory networks where miRNAs 
modulate the expression of transcription factors and transcription factors regulate 
miRNA levels to promote or maintain some important cell functions (1). On the other 
side, miRNA expression deregulation may contribute to the development of different 
human diseases, including cancer (5). 
In this study, we focused our attention on miR-382-5p, which resulted to be 
deregulated in several solid tumours and hematologic neoplasms (6-9). In particular, 
miR-382-5p upregulation has been reported in Acute Promyelocytic Myeloid 
Leukemia (AML-M3) (10, 11) and in Primary Myelofibrosis (PMF) patients (12). 
Despite an abnormal expression level of miR-382-5p has been described in these 
hematological malignancies, its role in normal hematopoiesis has not been described 
so far. Therefore, in order to characterize the function of miR-382-5p in myeloid 
development, we evaluated the effects of its overexpression on the commitment of 
human CD34+ hematopoietic stem/progenitor cells (HSPCs). Interestingly, we 
identified MAX dimerization protein 1 (MXD1) as a target of miR-382-5p, and 














































































































































































































































































































































































demonstrated that miR-382-5p favours granulocyte lineage at the expense of 
megakaryocyte one through MXD1 downregulation.   
   
MATERIALS AND METHODS 
Human CD34+ cells purification 
Umbilical cord blood (CB) samples were collected after normal deliveries, according 
to the institutional guidelines for discarded material (Clearance of Ethical Commitee 
for Human experimentation of Modena: Secretary office Saverio Santachiara, 
santachiara.saverio@policlinico.mo.it, approval date: 18.01.2005; approval file 
number # 793/CE). CB CD34+ cells were purified as previously described (13). After 
immunomagnetic separation, CD34+ cells were seeded in 24-well plates at 5 × 
105/ml in Iscove’s modified Dulbecco’s medium (IMDM) (Euroclone SPA, Milan, Italy) 
containing 20% human serum (Bio-Whittaker, Walkersville, MD, USA), stem cell 
factor (SCF) (50  ng/ml), FLT3-ligand (FLT3L) (50  ng/ml), thrombopoietin (TPO) 
(20  ng/ml), interleukin-6 (IL6) (10  ng/ml), and interleukin-3 (IL3) (10  ng/ml) (all 
from Miltenyi Biotec, Auburn, CA, USA). 
 
Electroporation of CD34+ cells 
Human CD34+ cells were transfected by using the 4D-Nucleofector System (Lonza 
Group Ltd, Basel, Switzerland) as previously reported (12). Briefly, after 24 hours of 
incubation in the cell-culture condition described above, CD34+ cells were 
nucleofected twice, once every 24 hours, with mirVana miR-382-5p mimic or mirVana 
miRNA mimic Negative Control #1 (m-NegCTR) (Life Technologies, Carlsbad, CA, 
USA). For each electroporation, 4 × 105 CD34+ cells were resuspended in 100 µL of 
P3 Primary Cell Solution (Lonza) containing 3 µg of mimic miRNA, and pulsed with 














































































































































































































































































































































































the program DS112. After each transfection, CD34+ cells were transferred into pre-
warmed fresh medium in 24-well plates (Euroclone) and maintained in the same 
culture conditions as described above. 
For small interfering RNAs (siRNAs) transfection, each sample was electroporated 3 
times, once every 24 hours, with 3 µg of a mix of 3 Silencer Select siRNA targeting 
human MXD1 (supplemental Table 1) (Life Technologies).  As previously described, 
CD34+ cells were nucleofected 24 hours after immunomagnetic purification, by using 
the P3 Primary Cell Solution (Lonza) and the electroporation protocol DS112. To 
exclude nonspecific effects caused by interfering RNA (RNAi) nucleofection, a 
sample transfected with a non-targeting siRNA negative control (ss-NegCTR; 
Silencer Select Negative Control #2 siRNA; Life Technologies) was included. 
Cells were analyzed 24 and 48 hours after the last nucleofection for both cell viability 
and miR-382-5p and/or MXD1 expression. 
Viability measurement was assessed by trypan blue exclusion assay 24 hours after 
the last nucleofection (14). In a Neubauer chamber, at least 100 cells were 
microscopically analyzed in duplicate for viability. The mean percentage of living cells 
of the two analyses was calculated. 
 
CD34+ cell-culture conditions, morphological and immunophenotypic analysis 
CD34+ cells were plated (5×105/mL) in IMDM with the addition of 20% BIT 9500 
serum substitute (bovine serum albumin, insulin, and transferrin; StemCell 
Technologies) 24 hours after the last nucleofection, in order to set up a multilineage 
cell culture (SCF, 50 ng/mL; FLT3L, 50 ng/mL; TPO, 20 ng/mL; IL-3, 10 ng/mL; IL-6, 
10 ng/mL; all cytokines from Miltenyi), megakaryocyte (MK) unilineage culture (TPO, 














































































































































































































































































































































































100 ng/mL), and granulocyte (GN) unilineage culture (SCF, 10 ng/mL; G-CSF, 25 
ng/mL) (13). 
Differentiation of CD34+ cells was monitored by morphological analysis of May-
Grunwald–Giemsa-stained cytospins and by flow cytometry analysis of CD34, CD14, 
CD66b, CD15, Glycophorin A (GPA), CD41 and CD42b surface antigen expression at 
day 5, 7, 10, and 12 after the last nucleofection. Images were captured by using an 
Ax10scopeA1 microscope equipped with AxioCam ERc 5S Digital Camera and Axion 
software 4.8 (all Carl Zeiss MicroImaging Inc.; Thornwood, NY, USA). The images 
were then processed with Adobe Photoshop 11.0.2 software. 
The following monoclonal antibodies (MoAbs) were used for flow cytometry analysis: 
phycoerythrin (PE)-conjugated mouse anti-human CD14 MoAb, fluorescein 
isothiocyanate (FITC)-conjugated mouse anti-human CD34 MoAb, FITC-conjugated 
mouse anti-human CD66b MoAb, FITC-conjugated mouse anti-human CD15 MoAb 
(all from Miltenyi Biotech; Auburn, CA, USA), FITC-conjugated mouse anti- human 
CD41 MoAb, PE-conjugated mouse anti-human CD42b MoAb, and PE-conjugated 
mouse anti-human GPA MoAb (all from Dako; Milano, Italia). After staining, cells 
were analyzed by using a BD FACSCanto II (BD Biosciences; San Jose, CA USA). At 
least 10,000 events were counted for each sample to ensure statistical relevance. 
 
MiR-382-5p expression during erythroid, megakaryocyte, granulocyte and 
mono-macrophage differentiation 
After immunomagnetic separation, CD34+ cells were seeded in 24-well plate at a 
density of 5 × 105/ml in IMDM (Euroclone SPA, Milan, Italy) containing 20% human 
serum (Bio-Whittaker, Walkersville, MD, USA), SCF 50  ng/ml, FLT3L 50  ng/ml, 
TPO 20  ng/ml, IL6 10  ng/ml, and IL3 10  ng/ml (all from Miltenyi Biotec, Auburn, 














































































































































































































































































































































































CA, USA). After a first phase of expansion, at 24 hours of culture (day 0) cells were 
seeded (5 × 105/ml) in IMDM added with 20% BIT (StemCell Technologies) in order 
to set up erythrocyte (EPO 0,4U/ml, SCF 10 ng/ml), megakaryocyte (TPO 100 
ng/ml), granulocyte (GCSF 25 ng/ml, SCF 10 ng/ml) and monocyte (MCSF 100 
ng/ml, SCF 20 ng/ml, IL6 20 ng/ml and Flt3L 50 ng/ml) unilineage cultures (13). 
CD34+ cells differentiation was monitored by morphological analysis of MGG-stained 
cytospins and by flow-cytometric analysis of differentiation marker expression. The 
medium was replaced every 2 days. MiR-382-5p expression level was detected by 
qRT-PCR at different time points (i.e. days 1, 2, 3, 5, 7, 9 and 12) after seeding cells 
in erythrocyte, megakaryocyte, granulocyte or mono-macrophage unilineage 
cultures. The day 0 sample was designated as the calibrator. 
 
Methylcellulose and collagen clonogenic assays 
Two different clonogenic assays were performed at 24 hours after the last 
nucleofection. The methylcellulose assay was carried out by plating CD34+ cells in 
MethoCultTM H4434 Classic (StemCell Technologies Inc.; Vancouver), as previously 
described (15). In addition, MK colony forming units (CFU-MK) were assayed in 
collagen-based medium, using a commercial MK assay detection kit (MegaCult-C; 
StemCell Technologies Inc.) as previously reported (16). 
 
RNA purification and quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) 
Total cellular RNA, including small RNAs, was isolated from CD34+ cells using the 
miRNeasy mini RNA isolation kit (Qiagen, Hilden, Germany) following the 
manufacturer’s recommendations. The purity and integrity of RNA samples were 














































































































































































































































































































































































determined by using disposable RNA chips (Agilent RNA 6000 Nano LabChip kit) and 
the Agilent 2100 Bioanalyzer (Agilent Technologies; Waldbrunn, Germany). 
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies; Wilmington, DE) 
was used to evaluate the RNA sample concentration, while 260/280 nm and 260/230 
nm ratios were used to assess the purity of RNA. 
cDNA was reverse-transcribed from total RNA (100 ng per sample) using the High-
Capacity cDNA Reverse Transcription Kit (Life technologies; Carlsbad, CA, USA), 
and real-time PCR was carried out in triplicate with TaqMan gene expression assays 
and Fast advanced master mix (all reagents from Life Technologies) by using an AB 
7900HT Fast Real-Time PCR System (Applied Biosystems) (17). Gene expression 
relative quantification (RQ) was achieved using the comparative cycle threshold (CT) 
method using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the 
housekeeping gene. The ss-NegCTR sample was considered as the calibrator, the 
RQ value was expressed as 2−ΔΔCT.  
For miRNA cDNA synthesis, 5 ng of total RNA was reverse-transcribed using the 
Taqman microRNA Reverse Transcription Kit and specific primers included in 
TaqMan MicroRNA assays. qRT-PCR was performed using TaqMan MicroRNA 
assays (Life Technologies) as described above and U6 snRNA as a housekeeping 
control. 
 
Luciferase reporter assays 
Predicted target sites of miR-382-5p were cloned into the Pme1 and XbaI sites of 
pmirGLO Dual-Luciferase miRNA Target Expression Vector (Promega Italia, Milano, 
Italy), following manufacturer's instructions. Every cloned plasmid contains the firefly 
luciferase gene upstream of a given miRNA binding site, and the Renilla luciferase 














































































































































































































































































































































































gene acting as a normalizer gene. Annealing oligonucleotides containing wild type 
miRNA binding sites were designed based on TargetScan 7.0 sequences 
(Supplemental Table 2). Mutated miRNA binding sites were obtained from the wild-
type miRNA binding sites by changing nucleotides 3-5 in the miRNA seed regions.  
K562 cells were electroporated by means of the Amaxa 4D-NucleofectorTM System, 
according to the manufacturer's instructions. Briefly, K562 cells were cultured at a 
density of 3×105 cells/mL 2 days before nucleofection. Cells were then transiently co-
nucleofected with either a miR-382-5p or m-NegCTR at a concentration of 3.6 μM 
and with either empty vector or miRNA binding site-containing construct at a 
concentration of 200 ng/sample. For each electroporation, 1x106 cells were 
resuspended in 100 μL of SF Cell line Solution (Lonza) and pulsed with the program 
FF120. Firefly and Renilla luciferase activities were measured 24 hours after 
electroporation using the Dual-Luciferase Reporter Assay System (Promega), and 
luminescence was recorded on a GloMax®-Multi+ Detection System with IntinctTM 
Software (Promega), according to the manufacturer’s protocol. 
In order to analyze the data, three levels of normalization were performed as 
previously described: firstly, firefly luciferase activity was normalized to that of Renilla 
luciferase as the internal control for nucleofection efficiency; secondly, the data were 
normalized to the effect of the miRNA mimic on the empty vector control reporter; 
lastly, the luminescence signals were normalized to the effect of the m-NegCTR on 
the corresponding miRNA binding site-containing construct (12). 
 
Western blot 
MXD1 protein level in both miR-382-5p-overexpressing cells and MXD1-siRNA 
transfected CD34+ cells was detected by Western blot analysis. Briefly, cells were 














































































































































































































































































































































































harvested, washed twice with ice-cold PBS and lysed (5 × 105 cells/50 μl of lysis 
buffer) in 50 mM Tris (tris(hydroxymethyl)aminomethane)-Cl (pH 7.4), 150 mM NaCl, 
10 mM KCl, 1 mM EDTA, 20 mM NaF, 0.25% Na doexycholate, 5 mM dithiothreitol 
(DTT), 1% Nonidet P-40, and protease inhibitors (Complete, catalog #1697498, 
Roche, Milano, Italy). Total cell lysates (30 μg for each sample) were loaded onto 
10% SDS-polyacrylamide gel and blotted on nitrocellulose membrane. The 
membranes were stained with Red Ponceau to control loading and transfer. 
Membranes were then pre-blocked in blocking solution, composed by 5% bovine 
serum albumin (BSA) in 0.1% TBST, for 1 hour at room temperature (RT), and 
incubated with primary antibodies: 1) rabbit polyclonal anti-MXD1 antibody (1:500 
dilution, anti-Mad1 (C19), catalog #sc-222, Santa Cruz Biotechnology Inc., 
Heidelberg, Germany) at 4 °C overnight; 2) rabbit polyclonal anti-actin antibody 
(1:2000 dilution, Thermo Fisher Scientific Inc., Waltham, MA, USA, catalog #PA1-
16889) for 1 hour at RT. After three washes with TBST, blots were incubated with 
HRP conjugated goat anti-rabbit secondary antibody (1:10000 dilution, catalog #sc-
2004, Santa Cruz Biotechnology, Inc.) for 1 hour at RT and revealed by BM 
Chemiluminescence Blotting Substrate (POD) (Roche). 
 
Statistical analysis 
The statistics used for data analysis in overexpression/silencing experiments and 
luciferase reporter assays were based on 2-tailed Student t tests for averages 
comparison in paired samples. Data were analyzed by using Microsoft Excel 
(Microsoft Office, 2008 release) and are reported as mean ± standard error of the 
mean (SEM). P < .05 was considered significant. 
 















































































































































































































































































































































































MiR-382-5p overexpression in CD34+ cells 
In order to study the role of miR-382-5p in HSPC commitment, miR-382-5p was 
overexpressed in CD34+ cells. By means of qRT-PCR, we confirmed that the miRNA 
expression level was upregulated upon miR-382-5p mimic transfection at 24 and 48 
hours (RQ ± SEM, 1677 ± 383, P < .05 and 625 ± 85 P < .01, respectively) after the 
last nucleofection (Figure 1A). Trypan blue exclusion assay showed that cell viability 
was about 90% in both m-NegCTR and miR-382-5p samples (Figure S1A). 
Flow cytometry analysis of MK differentiation markers performed on TPO unilineage 
culture at days 5, 7, 10, and 12 showed that miR-382-5p overexpression induces a 
significant decrease in the CD41+ cell fraction compared with the m-NegCTR control 
(Figure 1B). In addition, the mature megakaryocytic CD41+/CD42b+ population was 
similarly reduced at days 7 and 10 (Figure 1C). On the contrary, miR-382-5p 
overexpression in GCSF unilineage culture led to a significant increase in the 
percentage of CD66b+ and CD15+ cells at days 10 and 12 after the last 
nucleofection (Figure 1D-E). Similarly, miR-382-5p upregulation in multilineage 
culture conditions further confirmed these results (data not shown). Flow cytometry 
analysis of mono-macrophage and erythrocyte differentiation markers did not 
highlight any significant modulation of expression between miR-382-5p CD34+ cells 
and the m-NegCTR sample (data not shown). According to flow cytometry results, 
the morphologic analysis of MGG-stained cytospins obtained from TPO unilineage 
culture showed a remarkable reduction in MK precursors at different stages of 
maturation in miR-382-5p–overexpressing cells compared with control (Figure 1G, 
Panels i-iv).  Moreover, morphological evaluation of GCSF-treated cells clearly 
displayed a considerable enrichment in granulocytes in miR-382-5p sample (Figure 














































































































































































































































































































































































1H, Panels i-iv). Similarly, miR-382-5p upregulation in multilineage culture conditions 
further confirmed these results (Figure 2). Flow cytometry analysis of mono-
macrophage (CD14) and erythrocyte (GPA) markers did not highlight any significant 
modulation of expression between miR-382-5p CD34+ cells and the m-NegCTR 
sample (Figure S1, Panels B-D). 
Consistently with previous results, methylcellulose assay highlighted a remarkable 
increase in the percentage of granulocyte colony forming unit (CFU-G), whereas 
monocyte (CFU-M), erythroid (Burst-Forming Units (BFU-E) and CFU-E) and 
granulo-monocyte (CFU-GM) colonies were not significantly affected (Figure 3A). 
Furthermore, the collagen-based assay that supports the growth of MK progenitors in 
vitro showed that miR-382-5p overexpression causes a significant decrease in the 
CFU-MK percentage coupled with a significant increase of non-MK colonies (Figure 
3B). 
Since miR-382-5p interferes with lineage choice of CD34+ cells, we assessed its 
expression level in CD34+ and differentiated cells obtained from granulocyte, 
monocyte-macrophage, erythrocyte, and megakaryocyte unilineage culture 
conditions. As shown in figure S2, miR-382-5p expression level was decreased 
during the initial phase of megakaryocyte and erythroid unilineage cultures, while its 
expression increased in the last phases of differentiation. On the contrary, miR-382-
5p results upregulated during the granulocyte and monocyte-macrophage 
differentiation (Figure S2).  
Overall, these results indicated that miR-382-5p overexpression in CD34+ HSPCs 
enhances granulocyte differentiation while negatively interferes with the 
megakaryocyte one. 
 














































































































































































































































































































































































MiR-382-5p target prediction and validation by luciferase reporter assays 
In order to identify the molecular targets through which miR-382-5p modulates the 
MK and GN commitment in CD34+ HSPCs, several prediction algorithms (i.e. 
TargetScan, microRNA.org, PITA, etc.) were used. In a combinational analysis with 
these different tools we found out several predicted targets of miR-382-5p, which 
contain a putative binding site for miR-382-5p in their 3’-UTR. Next, we selected 
those genes known to be involved in MK and GN differentiation (i.e. FLI1, GATA2, 
MAF, MXD1, RUNX1, and SGK1) (Table 1) (18-22).   
First, we assessed whether miR-382-5p overexpression in CD34+ HSPCs led to the 
down-regulation of putative target expression by means of qRT-PCR. As shown in 
Figure 4A, all mRNAs were downregulated in miR-382-5p-overexpressing cells at 24 
hours after the last nucleofection. 
Finally, to confirm whether the downregulated mRNAs are real targets of miR-382-5p, 
we validated every putative miRNA-mRNA interaction by means of luciferase reporter 
assay. To this end, the predicted miRNA binding sites were cloned into the 3'-UTR of 
the Dual Luciferase pmirGLO vector and transiently transfected in K562 cells. 
Luciferase activity was measured in the presence of miR-382-5p mimic or m-
NegCTR and normalized using Renilla activity. As shown in Figure 4B, miR-382-5p 
overexpression significantly inhibited the luciferase activity in the sample transfected 
with the wild type miRNA binding site on MXD1 3'-UTR; conversely, the luciferase 
activity was not repressed by miR-382-5p overexpression in sample transduced with 
MXD1-mutated miRNA binding site. Likewise, miR-382-5p upregulation did not 
significantly reduce the luciferase activity in samples transduced with miRNA binding 
site of GATA2, FLI1, RUNX1, MAF and SGK1 (Figure 4B). According to luciferase 














































































































































































































































































































































































reporter assay results, Western blot analysis showed a marked reduction of MXD1 
protein level upon miR-382-5p overexpression (Figure 4C). 
 
MXD1 silencing in CD34+ cells 
To better characterize the role of miR-382-5p/MXD1 axis in myelopoiesis, we 
investigated whether MXD1 silencing could reproduce the effects mediated by miR-
382-5p overexpression on GN and MK differentiation. Therefore, CD34+ cells were 
transfected with a mixture of three Silencer Select siRNAs targeting MXD1 mRNA 
(supplemental Table 1) and with a non-targeting siRNA as a negative control (ss-
NegCTR). As shown in Figure S3 Panel A, cell viability was > 90% in all samples, 
without any significant differences between ss-NegCTR and MXD1-siRNA. The 
expression level of MXD1 in control samples and MXD1-siRNA cells was assessed 
by qRT-PCR and Western Blot analysis. As shown in Figure 5A, we obtained a 
significant MXD1 downregulation of MXD1 mRNA at 24 and 48 hours after the last 
nucleofection (RQ ± SEM, 0.34 ± 0.03, P < .001 and 0.48 ± 0.10, P < .01, 
respectively). Accordingly, the MXD1 protein level is remarkably decreased at 24 
hours post-nucleofection (Figure 5B).   
As observed for the miR-382-5p overexpression, MXD1 silencing led to a substantial 
decrease in the percentage of CD41+ and CD41+/CD42b+ cells at day 7 and 10 after 
the last nucleofection in MK unilineage culture (Figure 5C-D). At the same time, 
MXD1 silencing induces a significant increase in the percentage of CD66b+ and 
CD15+ cells compared with the ss-NegCTR sample (Figure 5E-F). Furthermore, the 
morphological analysis of MGG-stained cytospins showed a significant reduction in 
MK precursors (Figure 5H, Panels i-iv) and a significant expansion of granulocytes 
in MXD1-siRNA cells (Figure 5I, Panels i-iv). The same morphological differences 














































































































































































































































































































































































could be appreciated also in MGG-stained cytospins obtained from multilineage 
culture (Figure 5J, Panels i-iv).  
Conversely, we did not observe any modulation of GPA and CD14 expression upon 
MXD1 knockdown (Figure S3, Panels B-D).  
Finally, according to results obtained by means of clonogenic assay on miR-382-5p-
overexpressing cells, we found a significant increase in the percentage of CFU-G, 
while CFU-M, BFU-E/CFU-E and CFU-GM colonies were not significantly affected by 
MXD1 down-regulation (Figure 6A). In addition, the collagen-based assay confirmed 
that MXD1 silencing induces a decrease of MK progenitors as showed by a lower 
CFU-MK percentage in MXD1-siRNA sample compared with control (Figure 6B).  
Since the expression levels of the megakaryocyte transcription factors GATA2, FLI1, 
RUNX1, and MAF and of the kinase SGK1 were decreased upon miR-382-5p 
overexpression, although they have not been previously identified as 
functional targets, we still wondered whether MXD1 silencing could modulate their 
expression. By means of qRT-PCR, we showed that the mRNA levels of GATA2, 
RUNX1 and FLI1 were significantly downregulated in MXD1-silenced cells (Figure 




Growing evidence shows that miRNAs regulate stem cell-fate decision by modulating 
fundamental processes like self-renewal, proliferation and differentiation. For this 
reason, dysregulation of miRNA expression represents a common mechanism of 
tumorigenesis and cancer progression.  














































































































































































































































































































































































MiR-382-5p overexpression has been described in some hematological 
malignancies, such as PMF (12) and Acute Myeloid Leukemia (AML) (10, 11), even if 
its role in normal hematopoiesis was still unknown. 
Here we showed for the first time that miR-382-5p plays a critical role in 
hematopoiesis by influencing the lineage choice of CD34+ cells. In particular, we 
demonstrated that miR-382-5p supports the expansion of granulocyte lineage 
whereas negatively interferes with megakaryocyte commitment, as demonstrated by 
a significant increase of granulocyte precursors coupled to decrease of 
megakaryocyte ones in miR-382-5p-overexpressing cells (Figure 1-3).  
Next, in order to identify the molecular targets by which miR-382-5p regulates HSPC 
fate, we found by a prediction analysis several putative targets known to be involved 
in MK and GN differentiation (i.e. FLI1, GATA2, MAF, MXD1, RUNX1, and SGK1) 
(Table 1) (18-22), whose mRNA expression was decreased in miR-382-5p-
overexpressing cells (Figure 4A). Therefore, by means of luciferase reporter assay 
we were able to validate the MXD1-miR-382-5p interaction (Figure 4B). Moreover, 
as shown in figure 4C, MXD1 protein level is strongly reduced in miR-382-5p-
overexpressing cells compared to control.  
MXD1, also known as MAD1, is a transcriptional repressor involved in the 
MYC/MAX/MAD pathway, one of the best known network that controls cell 
proliferation and differentiation (23). In fact, MXD1 interacts with MAX antagonizing 
MYC/MAX dimer activity (23). Queva et al. showed that MXD1 is rapidly induced 
upon cell differentiation, when MYC expression is downregulated and cells begin to 
exit the cell cycle acquiring a differentiated phenotype (24).  
Here we demonstrated that MXD1 knockdown reproduces the effects of miR-382-5p 
overexpression on CD34+ HSPC differentiation leading to a significant decrease of 














































































































































































































































































































































































megakaryocyte precursors coupled to increase of granulocyte ones (Figure 5 and 6). 
According to our results, the increased expression of MXD1 has been previously 
reported also in megakaryocytes obtained in vitro from human CD34+ cells (21). 
Therefore, the MXD1 expression in CD34+ cells seems to be essential for 
megakaryocyte differentiation; in fact, the MK transcription factors GATA2, FLI1 and 
RUNX1 were significantly decreased after MXD1 silencing (Figure 7) (18), 
suggesting that the expression of these genes could be regulated by MXD1 in a 
direct or indirect way. For instance, the downregulation of GATA2, FLI1 and RUNX1 
might be mediated by the MXD1-driven inhibition of a transcriptional repressor (i.e. 
BCL6) (25). Moreover, MXD1 can also heterodimerize with other proteins in addition 
to MAX (i.e. MLX), even if the function of these complexes as well as their targets 
has not been defined so far (26, 27). 
Two independent studies reported that MXD1 induces erythroid differentiation in 
human (28) and mouse (29) erithroleukemia cells. Here we showed that MXD1 
silencing did not impair erythroid differentiation in normal CD34+ cells, as 
demonstrated by the expression level of GPA (Figure S3, Panel C-D) and the 
percentage of red colonies (Figure 6A), which did not change after MXD1 
knockdown. A possible explanation for this different cellular behaviour is that normal 
CD34+ cells might express some proteins that could replace MXD1 during erythroid 
differentiation. 
Furthermore, our data demonstrated that MXD1 plays an important role in 
granulocyte differentiation; in fact, the MXD1 knockdown enhances the fraction of 
granulocyte precursors both in liquid and semisolid cultures (Figure 5 and 6). In 
agreement with our data, Foley et al. demonstrated that MXD1 knockout in mice 
affects the granulocyte lineage by reducing cell cycle withdrawal during the late stage 














































































































































































































































































































































































of granulocyte differentiation, resulting in increased frequency of granulocytic 
precursors in the bone marrow (20). Moreover, another mechanism by which MXD1 
inhibition could favour the expansion of granulocyte fraction is mediated by the 
reduction of MAX/MXD1 heterodimers arising in an increased availability of MAX 
protein, which in turn activates C/EBPalpha, a master regulator of granulocyte 
commitment (30). 
Overall, these results demonstrated that miR-382-5p favours the expansion of 
granulocyte precursors through MXD1 down-regulation. Noteworthy, two 
independent research groups reported an high level of miR-382-5p in Acute 
promyelocytic leukemia (APL) patients with t(15;17) (10, 11). This subtype of AML is 
characterized by PML-RARalpha fusion oncoprotein that is responsible for the 
differentiation block of leukemic promyelocytes. Of note, as demonstrated by Khan et 
al., PML-RARalpha can interact with MXD1 and inhibits its transcriptional repression 
activity (31). This evidence suggests that the deregulation of miR-382-5p/MXD1 axis 
contributes to the development of APL in cooperation with PML-RARalpha fusion 
protein; therefore, miR-382-5p could be considered as a novel molecular target for 
APL treatment.  
In summary, our results demonstrated that miR-382-5p supports the expansion of 
granulocyte lineage whereas negatively interferes with megakaryocyte one through 
MXD1 down-regulation. To our knowledge, this is the first study describing miR-382-
5p/MXD1 axis as a crucial regulator of hematopoietic stem cell fate.  
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Figure 1. Effect of miR-382-5p overexpression on CD34+ HSPC differentiation. 
(A) The expression level of miR-382-5p at 24 and 48 hours after the last 
nucleofection was measured by qRT-PCR and data reported as Relative Quantity. 
(B-C) Flow cytometry results of CD41, and CD42b expression at day 5, 7, 10, and 12 
after the last nucleofection in MK unilineage culture. (D-E) Flow cytometry results of 
CD66b, and CD15 expression at day 7, 10, and 12 after the last nucleofection in GN 
unilineage culture. (F) Morphological analysis of m-NegCTR (i) and miR-382-5p (ii) 
nucleofected cells after May-Grünwald-Giemsa staining at 24 hours after the last 
nucleofection (before seeding in unilineage and multilineage cultures) in a 
representative experiment. Magnification ×1000. (G) Morphological analysis of m-
NegCTR (i-ii) and miR-382-5p (iii-iv) nucleofected cells after May-Grünwald-Giemsa 














































































































































































































































































































































































staining at days 10 of MK unilineage culture in a representative experiment. 
Magnification ×1000. (H) Morphological analysis of m-NegCTR (i-ii) and miR-382-5p 
(iii-iv) nucleofected cells after May-Grünwald-Giemsa staining at days 10 of GN 
unilineage culture in a representative experiment. Magnification ×1000.  
Values are reported as mean ± standard error of the mean (SEM). **, P < .01 versus 
m-NegCTR; *, P < .05 versus m-NegCTR. The results come from five independent 
experiments. Abbreviations: m-NegCTR, mimic negative control; h, hours. 
 
  
















































































































































































































































































































































































Figure 2. Effect of miR-382-5p overexpression on CD34+ HSPC differentiation 
in multilineage culture.  
(A) Flow cytometry results of CD41 expression at day 5, 7, 10, and 12 after the last 
nucleofection in multilineage culture. (B-C) Flow cytometry results of CD66b, and 
CD15 expression at day 7, 10, and 12 after the last nucleofection in multilineage 
culture. (D) Morphological analysis of m-NegCTR (i-ii) and miR-382-5p (iii-iv) 
nucleofected cells after May-Grünwald-Giemsa staining at day 10 of multilineage 
culture in a representative experiment. Magnification ×1000.  
Values are reported as mean ± standard error of the mean (SEM). **, P < .01 versus 
m-NegCTR; *, P < .05 versus m-NegCTR. The results come from five independent 




















































































































































































































































































































































































Figure 3. Methylcellulose and collagen-based clonogenic assays upon miR-
382-5p overexpression in CD34+ HSPCs.  
(A) Results of the statistical analysis of methylcellulose clonogenic assay. The cells 
were plated 24 hours after the last nucleofection and scored after 14 days. (B) 
Results of the statistical analysis of collagen-based clonogenic assay. The cells were 
plated 24 hours after the last nucleofection and scored after 12 days.  
Values are reported as mean ± standard error of the mean (SEM). **, P < .01 versus 
m-NegCTR; *, P < .05 versus m-NegCTR. The results come from five independent 
experiments. Abbreviations: CFU, colony-forming unit; BFU, burst-forming units; MK, 
megakaryocyte; G, granulocyte; M, monocyte; E, erythroid; GM, granulo-monocyte. 
 
  
















































































































































































































































































































































































Figure 4. Identification of miR-382-5p targets.  
(A) The expression levels of the putative targets were measured by qRT-PCR in miR-
382-5p-overexpressing CD34+ cells at 24 hours after the last nucleofection. Data are 
reported as Relative Quantity. Results come from five independent experiments. 
Values are reported as mean ± SEM; ***, P < .001 versus m-NegCTR; **, P < .01 
versus m-NegCTR; *, P < .05 versus m-NegCTR. (B) Results of the luciferase 
reporter assays performed with wild type and mutated miRNA binding sites. 
Normalized luciferase activity of K562 cells nucleofected with miR-382-5p mimics 
and pmirGLO vectors containing the putative miRNA binding sites. Firefly luciferase 
activity was measured 24 hours after the nucleofection and normalized to Renilla 
luciferase activity. Each bar represents the luciferase activity upon miRNA 
overexpression normalized on the value of the same 3'-UTR luciferase vector upon 














































































































































































































































































































































































m-NegCTR transfection. (C) Western blot analysis of MXD1 protein levels in lysates 
from miR-382-5p and m-NegCTR transfected CD34+ cells at 24 hours after the last 
nucleofection. β-actin protein level is reported as loading control. 
Values are reported as mean ± SEM; *, P < .05 versus mutated miRNA binding site. 
Results come from three independent experiments performed in duplicate.  
 
  
















































































































































































































































































































































































Figure 5. Effect of MXD1 silencing on CD34+ HSPC differentiation.  
(A) The expression level of MXD1 at 24 and 48 hours after the last nucleofection was 
measured by qRT-PCR and data reported as Relative Quantity. (B) Western blot 
analysis of MXD1 protein level in lysates from MXD1 siRNA and ss-NegCTR 
transfected CD34+ cells at 24 hours after the last nucleofection. β-actin protein level 
is reported as loading control.  (C-D) Flow cytometry results of CD41, and CD42b 
expression at day 5, 7, 10, and 12 after the last nucleofection in MK unilineage 
culture. (E-F) Flow cytometry results of CD66b, and CD15 expression at day 7, 10, 
and 12 after the last nucleofection in GN unilineage culture. (G) Morphological 














































































































































































































































































































































































analysis of negative control (ss-NegCTR) (i) and MXD1 short interfering RNA (MXD1 
siRNA) (ii) samples after May–Grünwald–Giemsa staining at 24 hours after the last 
nucleofection (before seeding in unilineage and multilineage cultures) in a 
representative experiment. Magnification ×1000. (H) Morphological analysis of 
negative control (ss-NegCTR) (i-ii) and MXD1 short interfering RNA (MXD1 siRNA) 
(iii-iv) samples after May–Grünwald–Giemsa staining at day 10 of MK unilineage 
culture in a representative experiment. Magnification ×1000. (I) Morphological 
analysis of ss-NegCTR (i-ii) and MXD1 siRNA (iii-iv) samples after May-Grünwald-
Giemsa staining at day 10 of GN unilineage culture in a representative experiment. 
Magnification ×1000. (J) Morphological analysis of ss-NegCTR (i-ii) and MXD1 siRNA 
(iii-iv) samples after May-Grünwald-Giemsa staining at day 10 of multilineage culture 
in a representative experiment. Magnification ×1000. 
Values are reported as mean ± standard error of the mean (SEM). ***, P < .001 
versus ss-NegCTR; **, P < .01 versus ss-NegCTR; *, P < .05 versus ss-NegCTR. 
The results come from five independent experiments. Abbreviations: ss-NegCTR, 
siRNA negative control; siRNA, small interfering RNA; h, hours. 
 
  
















































































































































































































































































































































































Figure 6. Methylcellulose and collagen-based clonogenic assays upon MXD1 
silencing in CD34+ HSPCs.  
(A) Results of the statistical analysis of methylcellulose clonogenic assay. The cells 
were plated 24 hours after the last nucleofection and scored after 14 days. (B) 
Results of the statistical analysis of collagen-based clonogenic assay. The cells were 
plated 24 hours after the last nucleofection and scored after 12 days. 
Values are reported as mean ± standard error of the mean (SEM). **, P < .01 versus 
ss-NegCTR; *, P < .05 versus ss-NegCTR. The results come from five independent 
experiments. Abbreviations: CFU, colony-forming unit; BFU, burst-forming units; MK, 
megakaryocyte; G, granulocyte; M, monocyte; E, erythroid; GM, granulo-monocyte. 
 
  
















































































































































































































































































































































































Figure 7. MXD1 downstream regulation of GATA2, FLI1 and RUNX1.  
The expression levels of GATA2, FLI1, RUNX1, MAF, and SGK1 were measured by 
qRT-PCR in MXD1 siRNA-transfected CD34+ cells at 24 hours after the last 
nucleofection. Data are reported as Relative Quantity. Values are reported as mean 
± standard error of the mean (SEM). The results come from five independent 
experiments. **, P < .01 versus ss-NegCTR; *, P < .05 versus ss-NegCTR. 
 
  
















































































































































































































































































































































































Figure S1. Effect of miR-382-5p overexpression in CD34+ HSPC on cell viability 
and differentiation of the erythroid and monocyte/macrophage lineages.  
(A) Cell viability assessed by trypan blue exclusion assay in m-NegCTR or miR-382-
5p samples at 24 hours after the last nucleofection. (B) Expression of 
monocyte/macrophage marker CD14 at day 10, and 12 after the last nucleofection in 
multilineage culture. (C) Expression of erythrocyte marker GPA at day 7, and 10 after 
the last nucleofection in serum-free multilineage culture. (D) Expression of 
erythrocyte marker GPA at day 5, 7, and 10 after the last nucleofection in EPO 
unilineage culture.  
Values are reported as mean ± standard error of the mean (SEM). *, P < .05 versus 
m-NegCTR. The results come from three independent experiments. Abbreviations: 
m-NegCTR, mimic negative control. 
 
  
















































































































































































































































































































































































Figure S2. MiR-382-5p expression during erythroid, megakaryocyte, 
granulocyte and mono-macrophage differentiation. 
After 24 hours of culture (day 0) the cells were seeded in erythrocyte, 
megakaryocyte, granulocyte and monocyte unilineage cultures. CD34+ cells 
differentiation was monitored by morphological analysis of MGG-stained cytospins at 
day 9. MiR-382-5p expression level was detected by qRT-PCR at different time 
points (i.e. days 1, 2, 3, 5, 7, 9 and 12) and data reported as log10 of the Relative 
Quantity (RQ). The day 0 sample was designated as the calibrator sample. 
Values are reported as mean ± standard error of the mean (SEM). The results come 
from two independent experiments. Abbreviations: Relative Quantity, RQ. 
 
  
















































































































































































































































































































































































Figure S3. Effect of MXD1 silencing in CD34+ HSPC on cell viability and 
differentiation of the erythroid and monocyte/macrophage lineages.  
(A) Cell viability assessed by trypan blue exclusion assay in ss-NegCTR or MXD1-
siRNA samples at 24 hours after the last nucleofection. (B) Expression of 
monocyte/macrophage marker CD14 at day 10 and 12 after the last nucleofection in 
multilineage culture. (C) Expression of erythrocyte marker GPA at day 7, and 10 after 
the last nucleofection in serum-free multilineage culture. (D) Expression of 
erythrocyte marker GPA at day 5, 7, and 10 after the last nucleofection in EPO 
unilineage culture.  
Values are reported as mean ± standard error of the mean (SEM). *, P < .05 versus 
ss-NegCTR. The results come from three independent experiments. Abbreviations: 
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